The role of the triggering receptor expressed on myeloid cells-1 (TREM-1) in non-bacterial infections

Matos, Amanda de Oliveira; Dantas, Pedro Henrique Dos Santos; Silva‐Sales, Marcelle; Sales‐Campos, Helioswilton

doi:10.1080/1040841x.2020.1751060

Cited by 36 publications

(29 citation statements)

References 114 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several stimuli can regulate TREM-1 expression ( Figure 2). Increased TREM-1 surface levels and/or sTREM-1 release were demonstrated in vitro in both mouse and human Mn/macrophages in response to PRR activation by bacterial and viral PAMPs [37,45,168,[174][175][176][177][178][179][180][181][182] and bacteria challenge [45,162,183], and in vivo in animals [162,168,182,[184][185][186][187][188][189] and patients [162,181,185,[190][191][192] suffering from bacterial, fungal, and viral infections. In addition, pro (TNFα)-and anti-(TGF-β, IL-10) inflammatory cytokines can increase and abrogate, respectively, TREM-1 expression [171,193].…”

Section: Trem-1 Structure and Expression Regulation In Mpsmentioning

confidence: 99%

“…The TREM-1 role as an amplifier of inflammatory responses was confirmed in experimental models of septic shock and other infectious conditions. Recent studies described the TREM-1 involvement in viral and parasite-associated infections and its potential as a biomarker in these diseases [181,189,192]. The pharmacologic inhibition of TREM-1 signaling by administration of the TREM-1/Fc fusion protein or siRNAs partially protected animals from acute inflammation and death induced by microbial TLR ligands [37,154,161,162,168,181,186,[214][215][216].…”

Section: Trem-1 Role In Inflammatory Responses and Infectious/non-infmentioning

confidence: 99%

See 1 more Smart Citation

Targeting Mononuclear Phagocyte Receptors in Cancer Immunotherapy: New Perspectives of the Triggering Receptor Expressed on Myeloid Cells (TREM-1)

Raggi

Bosco

2020

Cancers

View full text Add to dashboard Cite

Inflammatory cells are major players in the onset of cancer. The degree of inflammation and type of inflammatory cells in the tumor microenvironment (TME) are responsible for tilting the balance between tumor progression and regression. Cancer-related inflammation has also been shown to influence the efficacy of conventional therapy. Mononuclear phagocytes (MPs) represent a major component of the inflammatory circuit that promotes tumor progression. Despite their potential to activate immunosurveillance and exert anti-tumor responses, MPs are subverted by the tumor to support its growth, immune evasion, and spread. MP responses in the TME are dictated by a network of stimuli integrated through the cross-talk between activatory and inhibitory receptors. Alterations in receptor expression/signaling can create excessive inflammation and, when chronic, promote tumorigenesis. Research advances have led to the development of new therapeutic strategies aimed at receptor targeting to induce a tumor-infiltrating MP switch from a cancer-supportive toward an anti-tumor phenotype, demonstrating efficacy in different human cancers. This review provides an overview of the role of MP receptors in inflammation-mediated carcinogenesis and discusses the most recent updates regarding their targeting for immunotherapeutic purposes. We focus in particular on the TREM-1 receptor, a major amplifier of MP inflammatory responses, highlighting its relevance in the development and progression of several types of inflammation-associated malignancies and the promises of its inhibition for cancer immunotherapy.

show abstract

Section: Trem-1 Structure and Expression Regulation In Mpsmentioning

confidence: 99%

Section: Trem-1 Role In Inflammatory Responses and Infectious/non-infmentioning

confidence: 99%

Targeting Mononuclear Phagocyte Receptors in Cancer Immunotherapy: New Perspectives of the Triggering Receptor Expressed on Myeloid Cells (TREM-1)

Raggi

Bosco

2020

Cancers

View full text Add to dashboard Cite

show abstract

“…Our findings through functional enrichment analyses using Ingenuity Pathway Analysis revealed inflammation, senescence, and apoptosis as some of the most enriched signaling pathways in aged lungs. Concerning inflammation, the most upregulated gene was TREM-1, a receptor of the innate immune system, expressed primarily by myeloid cells and associated with proinflammatory responses [ 17 ]. Likewise, toll-like receptor signaling (TLR) was also upregulated.…”

Section: Discussionmentioning

confidence: 99%

Transcriptomic profile of the mice aging lung is associated with inflammation and apoptosis as important pathways

Calyeca

Balderas-Martínez

Selman

et al. 2021

Aging

View full text Add to dashboard Cite

Aging is a universal biological process characterized by a progressive deterioration in functional capacity and an increased risk of morbidity and mortality over time. In the lungs, there are considerable changes in lung structure and function with advancing age; however, research on the transcriptomic profile implicated in this process is scanty. In this study, we addressed the lung transcriptome changes during aging, through a global gene expression analysis of normal lungs of mice aged 4- and 18-months old. Functional pathway enrichment analysis by Ingenuity Pathway Analysis (IPA) revealed that the most enriched signaling pathways in aged mice lungs are involved in the regulation of cell apoptosis, senescence, development, oxidative stress, and inflammation. We also found 25 miRNAs significantly different in the lungs of old mice compared with their younger littermates, eight of them upregulated and 17 downregulated. Using the miRNet database we identified TNFα, mTOR, TGFβ, WNT, FoxO, Apoptosis, Cell cycle, and p53 signaling pathways as the potential targets of several of the dysregulated miRNAs supporting that old lungs have increased susceptibility for apoptosis, inflammation, and fibrosis. These findings reveal differential expression profiles of genes and miRNAs affecting cell survival and the inflammatory response during lung aging.

show abstract

“…Moreover, patients with COVID-19 present multiple hematological abnormalities, of which lymphopenia and thrombocytopenia were prominent (14). (23)(24)(25)(26)(27)(28)(29). Immune responses against to virus and bacterial are modulated by activation of TREM-1 in macrophages.…”

Section: Introductionmentioning

confidence: 99%

“…The sTREM-1 is a 27kDa polypeptide in wich the with the extracellular domain is released from the cell surface by action of metalloproteinases (36). Interestingly, the serum sTREM-1 level measurements could be a valuable diagnostic biomarker and may be useful in predicting severe prognosis in diseases related to inflammatory processes, as seen in septic patients, Hepatitis B virus, Human Immunodeficiency virus (HIV), Crimean Congo Hemorrhagic Fever and Mycobacterium tuberculosis infections (27,33,(37)(38)(39).…”

Section: Introductionmentioning

confidence: 99%

Prognostic value of sTREM-1 in COVID-19 patients: a biomarker for disease severity and mortality

Neto

Carvalho

Pimentel

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: The uncontrolled inflammatory response plays a critical role in the novel coronavirus disease (COVID-19) and triggering receptor expressed on myeloid cells-1 (TREM-1) is thought to be intricate to inflammatory signal amplification. This study aims to investigate the association between soluble TREM-1 (sTREM-1) and COVID-19 as a prognostic biomarker to predict the disease severity, lethality and clinical management.Methods: We enrolled 91 patients with COVID-19 in domiciliary care (44 patients) or in hospital care (47 patients), who were classified after admission into mild, moderate, severe and critical groups according to their clinical scores. As non-COVID-19 control, 30 healthy volunteers were included. Data on demographic, comorbidities and baseline clinical characteristics were obtained from their medical and nurse records. Peripheral blood samples were collected at admission and after hospitalization outcome to assess cytokine profile and sTREM-1 level by specific immunoassays Results: Within COVID-19 patients, the highest severity was associated with the most significant elevated plasma levels sTREM-1. Using receiver operating curve analysis (ROC), sTREM-1 was found to be predictive of disease severity (AUC= 0.988) and the best cut-off value for predicting in-hospital severity was ≥ 116.5 pg/mL with the sensitivity for 93.3% and specificity for 95.8%. We also described the clinical characteristics of these patients and explored the correlation with markers of the disease aggravation. The levels of sTREM-1 were positively correlated with IL-6, IL-10, blood neutrophils counts, and critical disease scoring (r= 0.68, p<0.0001). On the other hand, sTREM-1 level was significantly negative correlated with lymphocytes counting, and mild disease (r= -0.42, p<0.0001). Higher levels of sTREM-1 were related to poor outcome and death, patients who received dexamethasone tended to have lower sTREM-1 levels. Conclusion: Our results indicated that sTREM-1 in COVID-19 is associated with severe disease development and a prognostic marker for mortality. The use of severity biomarkers such as sTREM-1 together with patients clinical scores could improve the early recognition and monitoring of COVID-19 cases with higher risk of disease worsening. Key words: COVID-19; sTREM-1; Inflammation; Biomarker; Severity; Mortality.

show abstract

The role of the triggering receptor expressed on myeloid cells-1 (TREM-1) in non-bacterial infections

Cited by 36 publications

References 114 publications

Targeting Mononuclear Phagocyte Receptors in Cancer Immunotherapy: New Perspectives of the Triggering Receptor Expressed on Myeloid Cells (TREM-1)

Targeting Mononuclear Phagocyte Receptors in Cancer Immunotherapy: New Perspectives of the Triggering Receptor Expressed on Myeloid Cells (TREM-1)

Transcriptomic profile of the mice aging lung is associated with inflammation and apoptosis as important pathways

Prognostic value of sTREM-1 in COVID-19 patients: a biomarker for disease severity and mortality

Contact Info

Product

Resources

About